ARCHIVES

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

This article is from The Cancer Letter archive.

Vol. 09 No. 46 | December 2, 1983

Download PDF Visit The Full Archive

Related Articles

Senate Democrats Include $1 Billion Boost To NIH In Economic Stimulus Package.

November 21, 2008

Memantine Can Delay Onset Of Cognitive Function Decline

November 30, 2012

FDA Revises Package Insert, Seeks To Limit Product Liability Suits In State Courts.

January 20, 2006

House DoD Report Provides $15 Million For Lung Cancer Screening

October 23, 2009

NCI Drops Protocol Review Requirement To Encourage firs To List Trials On PDQ

October 24, 1997

Coalitions Diverge On NIH Role, Agree On Need For More Basic Research

February 19, 1993